|
시장보고서
상품코드
1867544
세계의 압타머 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)Aptamers - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
세계의 압타머 시장 규모는 2024년에 4억 1,300만 달러로 평가되었고, 2025-2031년의 예측 기간에 CAGR 15.7%로 성장하여 2031년까지 11억 7,800만 달러에 이를 것으로 예측됩니다.
앱타머는 RNA 또는 DNA에서 유래한 고친화성 분자입니다. 이들은 일반적으로 '지수적 농축에 의한 리간드의 계통적 진화'(SELEX)라는 합성 공정을 통해 생성됩니다. 앱타머라는 명칭은 라틴어 'aptus(적합하다)'에서 유래되었습니다. 이는 표적 분자에 대해 높은 특이성과 친밀도를 가지고 결합한다는 것을 의미합니다. 앱타머는 높은 친화력과 특이성을 가지고 다양한 표적과 상호작용하는 단쇄 핵산입니다. 해당 표적 단백질의 생물학적 기능을 억제하는 것으로 입증되었으며, SELEX(Systematic Evolution of Ligands by EXponential enrichment)라고도 불리는 in vitro 선택 과정을 통해 확인할 수 있습니다. 핵산이기 때문에 화학적 또는 효소적으로 합성할 수 있습니다.
mRNA 백신과 siRNA 의약품이 임상적으로 성숙해가는 가운데, 핵산 치료 플랫폼의 중요한 구성요소인 앱타머는 표적치료, 세포 인식, 정밀 전달의 우월성으로 주목받고 있습니다. 바이오제약 기업, 합성생물학 혁신 기업, 주요 체외진단(IVD) 기업들은 압타머 기술을 전략적 파이프라인에 통합하여 종양학, 안과학, 자가면역질환, 바이러스 감염 등 다양한 분야에 적용을 확대하고 있습니다. 핵산 의약품과 정밀 분자진단에 대한 정부의 이니셔티브와 투자 지원은 앱타머 개발에 유리한 정책적, 재정적 지원을 제공합니다.
높은 잠재력에도 불구하고 압타머 산업은 상용화 초기 단계에 있습니다. 비효율적인 표적 스크리닝, 생체 내 안정성의 한계, 산업 표준의 부재, 강력한 특허 장벽 등의 문제에 직면해 있습니다. 또한, 자원과 시장 접근성에서 기존 항체 공급업체의 우위도 임상 현장에서 앱타머의 채택을 제약하고 있습니다. 또한, 많은 지역에서 압타머 기반 제품의 규제 체계가 아직 개발 중이어서 임상시험 결과와 시장 진입 요건에 대한 불확실성이 존재합니다.
다운스트림 수요는 기초연구에서 임상 진단 및 치료 분야로 빠르게 이동하고 있습니다. 암 액상 생검, 신경 퇴행성 질환의 조기 검진, 표적 약물 전달 시스템과 같은 고성장 분야에서 앱타머는 상업적으로 유망한 도구로 부상하고 있습니다. 합성생물학 플랫폼 기업, 맞춤형 핵산 서비스 제공업체, CDMO도 앱타머를 서비스에 통합하여 응용 영역을 확장하고 전체 가치사슬에서 역할을 강화하고 있습니다.
이 보고서는 압타머 세계 시장에 대한 종합적인 분석을 제공하는 것을 목표로 합니다. 총 매출액, 주요 기업의 시장 점유율과 순위에 초점을 맞추어 지역별, 국가별, 유형별, 용도별 앱타머 분석을 포함하고 있습니다.
이 보고서는 2024년을 기준 연도로 하여 2020년부터 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함하여 앱타머 시장 규모, 추정치, 예측치를 매출액으로 제시하고 있습니다. 정량적 분석과 정성적 분석을 통해 독자들이 앱타머에 대한 사업/성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 포지셔닝 분석, 정보에 입각한 사업적 판단을 내릴 수 있도록 돕습니다.
시장 세분화
기업별
- TriLink BioTechnologies
- AptaBharat
- SomaLogic
- AM Biotechnologies
- Aptamer Sciences
- Base Pair Biotechnologies
- Aptamer Group
- Aptagen
- Aptus Biotech
- NeoVentures Biotechnology
- Ray Biotech
- Vivonics
유형별 부문
- DNA 기반 압타머
- RNA 기반 압타머
용도별 부문
- 연구개발
- Drug Discovery
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Aptamers was estimated to be worth US$ 413 million in 2024 and is forecast to a readjusted size of US$ 1178 million by 2031 with a CAGR of 15.7% during the forecast period 2025-2031.
Aptamers are high affinity molecules that are derived from RNA or DNA. These are normally generated using a synthetic process called "Systematic evolution of ligands by exponential enrichment" (SELEX). Aptamers receive their name from the Latin word aptus meaning "fit". This means they bind to the target molecules with high specificity and high affinity. Aptamers are short nucleic acids that interact with a variety of targets with high affinity and specificity. They have been shown to inhibit biological functions of cognate target proteins, and they are identifiable by an in vitro selection process, also termed SELEX (Systematic Evolution of Ligands by EXponential enrichment). Being nucleic acids, aptamers can be synthesized chemically or enzymatically.
As mRNA vaccines and siRNA drugs gain clinical maturity, aptamers-an essential part of the nucleic acid therapeutic platform-are drawing attention for their advantages in targeted therapy, cell recognition, and precision delivery. Biopharmaceutical companies, synthetic biology innovators, and leading IVD players are incorporating aptamer technologies into their strategic pipelines, expanding applications across oncology, ophthalmology, autoimmune diseases, and viral infections. Government initiatives and investment support for nucleic acid drugs and precision molecular diagnostics further provide favorable policies and financial backing for aptamer development.
Despite the high potential, the aptamer industry remains at an early commercialization stage. It faces challenges such as inefficient target screening, limited in vivo stability, lack of industrial standards, and strong patent barriers. Dominance by traditional antibody suppliers in resources and market access also constrains aptamer adoption in clinical settings. Moreover, regulatory frameworks for aptamer-based products are still evolving in many regions, posing uncertainties in clinical trial outcomes and market entry requirements.
Downstream demand is rapidly shifting from basic research to clinical diagnostics and therapeutics. In high-growth segments such as liquid biopsy for cancer, early screening for neurodegenerative disorders, and targeted drug delivery systems, aptamers are emerging as commercially promising tools. Synthetic biology platform companies, custom nucleic acid service providers, and CDMOs are also integrating aptamers into their offerings, expanding the application landscape and reinforcing their role across the value chain.
This report aims to provide a comprehensive presentation of the global market for Aptamers, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Aptamers by region & country, by Type, and by Application.
The Aptamers market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Aptamers.
Market Segmentation
By Company
- TriLink BioTechnologies
- AptaBharat
- SomaLogic
- AM Biotechnologies
- Aptamer Sciences
- Base Pair Biotechnologies
- Aptamer Group
- Aptagen
- Aptus Biotech
- NeoVentures Biotechnology
- Ray Biotech
- Vivonics
Segment by Type
- DNA-Based Aptamers
- RNA-Based Aptamers
Segment by Application
- Research and Development
- Drug Discovery
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Aptamers company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Aptamers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Aptamers in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Aptamers Product Introduction
- 1.2 Global Aptamers Market Size Forecast (2020-2031)
- 1.3 Aptamers Market Trends & Drivers
- 1.3.1 Aptamers Industry Trends
- 1.3.2 Aptamers Market Drivers & Opportunity
- 1.3.3 Aptamers Market Challenges
- 1.3.4 Aptamers Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Aptamers Players Revenue Ranking (2024)
- 2.2 Global Aptamers Revenue by Company (2020-2025)
- 2.3 Key Companies Aptamers Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Aptamers Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Aptamers
- 2.6 Aptamers Market Competitive Analysis
- 2.6.1 Aptamers Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Aptamers Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Aptamers as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 DNA-Based Aptamers
- 3.1.2 RNA-Based Aptamers
- 3.2 Global Aptamers Sales Value by Type
- 3.2.1 Global Aptamers Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Aptamers Sales Value, by Type (2020-2031)
- 3.2.3 Global Aptamers Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Research and Development
- 4.1.2 Drug Discovery
- 4.2 Global Aptamers Sales Value by Application
- 4.2.1 Global Aptamers Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Aptamers Sales Value, by Application (2020-2031)
- 4.2.3 Global Aptamers Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Aptamers Sales Value by Region
- 5.1.1 Global Aptamers Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Aptamers Sales Value by Region (2020-2025)
- 5.1.3 Global Aptamers Sales Value by Region (2026-2031)
- 5.1.4 Global Aptamers Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Aptamers Sales Value, 2020-2031
- 5.2.2 North America Aptamers Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Aptamers Sales Value, 2020-2031
- 5.3.2 Europe Aptamers Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Aptamers Sales Value, 2020-2031
- 5.4.2 Asia Pacific Aptamers Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Aptamers Sales Value, 2020-2031
- 5.5.2 South America Aptamers Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Aptamers Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Aptamers Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Aptamers Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Aptamers Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Aptamers Sales Value, 2020-2031
- 6.3.2 United States Aptamers Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Aptamers Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Aptamers Sales Value, 2020-2031
- 6.4.2 Europe Aptamers Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Aptamers Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Aptamers Sales Value, 2020-2031
- 6.5.2 China Aptamers Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Aptamers Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Aptamers Sales Value, 2020-2031
- 6.6.2 Japan Aptamers Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Aptamers Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Aptamers Sales Value, 2020-2031
- 6.7.2 South Korea Aptamers Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Aptamers Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Aptamers Sales Value, 2020-2031
- 6.8.2 Southeast Asia Aptamers Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Aptamers Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Aptamers Sales Value, 2020-2031
- 6.9.2 India Aptamers Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Aptamers Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 TriLink BioTechnologies
- 7.1.1 TriLink BioTechnologies Profile
- 7.1.2 TriLink BioTechnologies Main Business
- 7.1.3 TriLink BioTechnologies Aptamers Products, Services and Solutions
- 7.1.4 TriLink BioTechnologies Aptamers Revenue (US$ Million) & (2020-2025)
- 7.1.5 TriLink BioTechnologies Recent Developments
- 7.2 AptaBharat
- 7.2.1 AptaBharat Profile
- 7.2.2 AptaBharat Main Business
- 7.2.3 AptaBharat Aptamers Products, Services and Solutions
- 7.2.4 AptaBharat Aptamers Revenue (US$ Million) & (2020-2025)
- 7.2.5 AptaBharat Recent Developments
- 7.3 SomaLogic
- 7.3.1 SomaLogic Profile
- 7.3.2 SomaLogic Main Business
- 7.3.3 SomaLogic Aptamers Products, Services and Solutions
- 7.3.4 SomaLogic Aptamers Revenue (US$ Million) & (2020-2025)
- 7.3.5 SomaLogic Recent Developments
- 7.4 AM Biotechnologies
- 7.4.1 AM Biotechnologies Profile
- 7.4.2 AM Biotechnologies Main Business
- 7.4.3 AM Biotechnologies Aptamers Products, Services and Solutions
- 7.4.4 AM Biotechnologies Aptamers Revenue (US$ Million) & (2020-2025)
- 7.4.5 AM Biotechnologies Recent Developments
- 7.5 Aptamer Sciences
- 7.5.1 Aptamer Sciences Profile
- 7.5.2 Aptamer Sciences Main Business
- 7.5.3 Aptamer Sciences Aptamers Products, Services and Solutions
- 7.5.4 Aptamer Sciences Aptamers Revenue (US$ Million) & (2020-2025)
- 7.5.5 Aptamer Sciences Recent Developments
- 7.6 Base Pair Biotechnologies
- 7.6.1 Base Pair Biotechnologies Profile
- 7.6.2 Base Pair Biotechnologies Main Business
- 7.6.3 Base Pair Biotechnologies Aptamers Products, Services and Solutions
- 7.6.4 Base Pair Biotechnologies Aptamers Revenue (US$ Million) & (2020-2025)
- 7.6.5 Base Pair Biotechnologies Recent Developments
- 7.7 Aptamer Group
- 7.7.1 Aptamer Group Profile
- 7.7.2 Aptamer Group Main Business
- 7.7.3 Aptamer Group Aptamers Products, Services and Solutions
- 7.7.4 Aptamer Group Aptamers Revenue (US$ Million) & (2020-2025)
- 7.7.5 Aptamer Group Recent Developments
- 7.8 Aptagen
- 7.8.1 Aptagen Profile
- 7.8.2 Aptagen Main Business
- 7.8.3 Aptagen Aptamers Products, Services and Solutions
- 7.8.4 Aptagen Aptamers Revenue (US$ Million) & (2020-2025)
- 7.8.5 Aptagen Recent Developments
- 7.9 Aptus Biotech
- 7.9.1 Aptus Biotech Profile
- 7.9.2 Aptus Biotech Main Business
- 7.9.3 Aptus Biotech Aptamers Products, Services and Solutions
- 7.9.4 Aptus Biotech Aptamers Revenue (US$ Million) & (2020-2025)
- 7.9.5 Aptus Biotech Recent Developments
- 7.10 NeoVentures Biotechnology
- 7.10.1 NeoVentures Biotechnology Profile
- 7.10.2 NeoVentures Biotechnology Main Business
- 7.10.3 NeoVentures Biotechnology Aptamers Products, Services and Solutions
- 7.10.4 NeoVentures Biotechnology Aptamers Revenue (US$ Million) & (2020-2025)
- 7.10.5 NeoVentures Biotechnology Recent Developments
- 7.11 Ray Biotech
- 7.11.1 Ray Biotech Profile
- 7.11.2 Ray Biotech Main Business
- 7.11.3 Ray Biotech Aptamers Products, Services and Solutions
- 7.11.4 Ray Biotech Aptamers Revenue (US$ Million) & (2020-2025)
- 7.11.5 Ray Biotech Recent Developments
- 7.12 Vivonics
- 7.12.1 Vivonics Profile
- 7.12.2 Vivonics Main Business
- 7.12.3 Vivonics Aptamers Products, Services and Solutions
- 7.12.4 Vivonics Aptamers Revenue (US$ Million) & (2020-2025)
- 7.12.5 Vivonics Recent Developments
8 Industry Chain Analysis
- 8.1 Aptamers Industrial Chain
- 8.2 Aptamers Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Aptamers Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Aptamers Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
